POZEN, Inc. (NASDAQ:POZN)

CAPS Rating: 3 out of 5

A pharmaceutical company focused on developing products which can provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain and pain related conditions.

Recs

0
Player Avatar philsie1 (< 20) Submitted: 7/7/2008 1:33:56 PM : Outperform Start Price: $9.61 POZN Score: -37.46

Undervalued per earnings potential of Treximet and pipeline including PN and PA. Many catalysts coming in next couple months, sales data on Treximet, partner for PA and SPA acceptance. PN data later in year or early next year.

Featured Broker Partners


Advertisement